TRT vs Enclomiphene: Two Treatments That Push the Same System in Opposite Directions

Testosterone production runs on a feedback loop. The brain monitors circulating testosterone and estradiol and adjusts LH and FSH to match. LH tells the testes to make testosterone; FSH drives sperm production.

Give testosterone from outside and the brain reads the level as sufficient. LH and FSH fall, and the testes, no longer signaled, make less testosterone of their own and less sperm. Testicular volume often decreases.

Block the estrogen receptor at the pituitary and the brain under-reads the circulating signal. LH and FSH rise, and the testes are told to work harder. The testosterone is your own.

That is why enclomiphene only works where the testes can respond. In primary hypogonadism, where the testes themselves are the problem, LH and FSH are usually already high and raising them achieves nothing. That is exactly what the LH and FSH results on the secondary hypogonadism page are for.

This deserves its own section because it is the most consequential and most under-explained part of the choice.

Testosterone therapy suppresses spermatogenesis. The AUA guideline notes that it can leave men severely oligospermic or with no sperm at all, which is why exogenous testosterone has been studied as a male contraceptive. The guideline recommends that its long-term effect on sperm production be discussed with any man interested in future fertility.

Recovery after stopping usually happens, but slowly, and it is not certain. In the contraception studies the AUA cites, sperm counts in most men returned within months to a couple of years, and shorter use was associated with faster recovery. "Usually recovers" is not the same as "always recovers," and that difference matters most to the man it does not apply to.

Sperm banking is worth discussing before starting, including for men who are sure they will not want children later, because circumstances change and the option cannot be recovered afterward. A semen analysis gives a baseline.

Where fertility matters, the guideline allows other routes. The AUA says clinicians may use SERMs, hCG or aromatase inhibitors, alone or combined, in men with testosterone deficiency who want to maintain fertility. Enclomiphene is a SERM. What it does for any one man's sperm count is answered by testing, not assumed; enclomiphene and fertility covers what is known.

Testosterone has FDA-approved products, decades of clinical use and two major guidelines, from the Endocrine Society and the AUA, that set out who should receive it and how it is monitored. It is a controlled substance.

Enclomiphene is not FDA-approved. In June 2022 the FDA's Pharmacy Compounding Advisory Committee considered whether enclomiphene citrate should be added to the list of bulk substances pharmacies may compound under section 503A. The FDA proposed that it should not, the committee voted against adding it, and several members cited a lack of clinical efficacy evidence. What ACT 2 prescribes is compounded by a licensed pharmacy; the FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed. Enclomiphene is a component of clomiphene, but it is not the same product; enclomiphene vs Clomid sets out the difference.

It has its own effects. Mood changes, headache and hot flushes are reported, and visual disturbance is an uncommon but recognized SERM class effect that needs prompt review rather than tolerating. Vision side effects explains what to report.

Both treat a diagnosis, and the diagnosis comes first.

• Two morning testosterone measurements on separate days, plus symptoms. The Endocrine Society and the AUA both require it; a single low afternoon result is not a diagnosis. Getting the test right explains why.
• LH and FSH, which separate a testicular cause from a pituitary one and decide whether enclomiphene can work at all.
• Hematocrit and PSA at baseline, because both are monitored on testosterone.
• A search for reversible causes: sleep apnea, alcohol, opioids, weight and thyroid disease among them. Medications that lower testosterone covers one common group.
• An explicit fertility conversation, which is the one most often skipped.

The testosterone program is $249 for the first month, which carries the new-patient workup and the live visit, then $149 a month. It is priced as one program whichever preparation your clinician selects. Enclomiphene ODT is $129 a month with no separate first-month rate, so it costs less than either testosterone tier. That is a price comparison only, not a statement about which treatment suits you. Lab work is billed separately; the TRT cost page works through a first year of each, including panels.

• When the diagnosis is not confirmed. A borderline single reading is a reason to retest, not to treat. When your level is borderline covers what happens next.
• When a reversible cause is found. Treating sleep apnea or reviewing a medication can remove the question.
• When symptoms are not hormonal. Fatigue and low drive in midlife have a long list of causes; is it low T or just aging works through it.
• When there is a reason testosterone is unsafe, such as active prostate or breast cancer or an already raised hematocrit, and enclomiphene does not fit the cause.